gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · VNDAHealthcarePharmaceuticals

Vanda Pharmaceuticals Inc. (VNDA)

$3.88+3.47%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$3.88▼ 10.80% in range
Nov 4, 2025Low $3.75 · High $9.56Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Vanda Pharmaceuticals closed at $3.88 on Nov 4, up 3.47%, 59.4% below its 52-week closing high. Volume of 1.2M shares was 1.00× its 20-day average (close to normal).

Split-adjusted performance: -14.2% over one month, -47.8% over six months, -13.2% over one year.

In the quarter ended Sep 30, 2026, revenue was $69.81M, up 24.1% from a year earlier, with a net margin of -32.3%.

Short interest was 8.3M shares at the Oct 15 settlement, up 6.1% from the prior report (15.4% of float, 8.3 days to cover).

Market cap$234.6M60.5M shares
Revenue · quarter$69.8M+24.1% YoY
Diluted EPS$-0.37—
P/E · TTM—P/S 1.0×
Net margin-32.3%Gross 94.1%
Dividend yieldNone
52-week range3.75 – 9.56−59.4% from high
Volume1.2M1.00× 20-day avg
Volatility · 60d39.7%Annualised
Short % of float15.4%8.3 days to cover
Net cash$138.1MCash $140.5M
Next earnings—Not scheduled
Split-adjusted performance
1W −3.0%1M −14.2%3M −24.1%6M −47.8%YTD −56.0%1Y −13.2%3Y −10.6%5Y −78.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum27
Revenue growth69
Net margin51
Value (low P/E)—
Size50

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short8.3M+6.1% vs prior
Days to cover8.3Settled Oct 15
% of float15.4%
Short vol. 10d51.4%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
VNDAVanda Pharmaceuticals$3.88+3.47%−47.8%+24.1%−32.3%—$234.6M
CAMPCAMP4 Therapeutics$3.74−2.35%−7.9%+18.8%−1884.8%—$234.7MCompare
GLSIGreenwich LifeSciences$16.35+2.70%−29.1%———$240.0MCompare
ABEOAbeona Therapeutics$4.22−0.71%−29.8%+2745.0%−177.4%—$241.3MCompare
LABStandard BioTools$0.6160+0.85%−36.4%−0.9%69.6%1.8$243.1MCompare
SIGASIGA Technologies$3.15+1.29%−33.0%−49.5%30.4%—$226.3MCompare
IMRXImmuneering$3.76+2.17%−27.6%———$243.5MCompare
NATRNature's Sunshine Products$12.84+6.38%−51.1%+1.9%3.0%12.5$225.9MCompare
LFCRLifecore Biomedical$6.44+0.31%+29.8%—−20.9%—$244.1MCompare

News about Vanda Pharmaceuticals

All news →

No recent articles focused on Vanda Pharmaceuticals. 2 articles mention it in passing.

Quick answers

What does Vanda Pharmaceuticals do?
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY.
What is VNDA's market cap?
$234.62M, based on the Nov 4 close of $3.88.
Does Vanda Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of VNDA is sold short?
8.3M shares, 15.4% of float, as of Oct 15, 2026.
What sector is VNDA in?
Healthcare, in the Pharmaceuticals industry.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

HQ: Washington, DC533 employeesListed Apr 12, 2006vandapharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology